drugset / Trial / NCT01919944

Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P

NCT01919944

Phase 1 Completed 12 enrolled Vanda Pharmaceuticals
RandomizedCrossoverQuadruple-blindPrevention

Summary

The purpose of this study is to test whether VLY-686 can prevent or reduce the itch and dermatological reaction observed after healthy volunteers are injected with Substance P in comparison with placebo.

Timeline

Start
2013-08
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tradipitant Small molecule 20 mg Oral
Subject Tradipitant Small molecule 50 mg Oral
Subject Tradipitant Small molecule 100 mg Oral

Indications

No indication recorded.